Phenylephrine/ketorolac

Phenylephrine/ketorolac, sold under the brand name Omidria, is a combination drug used during cataract surgery[3] or intraocular lens replacement to prevent intraoperative miosis and to reduce postoperative pain.[1] It contains phenylephrine and ketorolac.[1]

Phenylephrine/ketorolac
Combination of
PhenylephrineAlpha-1 adrenergic receptor agonist
KetorolacNonsteroidal anti-inflammatory
Clinical data
Trade namesOmidria
AHFS/Drugs.comMonograph
License data
Routes of
administration		Intraocular
ATC code
Legal status
Legal status
Identifiers
KEGG

Phenylephrine/ketorolac was approved for medical use in the United States in May 2014,[4] and in the European Union in July 2015.[2]

References
  1. "Omidria- phenylephrine and ketorolac injection, solution, concentrate". DailyMed. 11 December 2017. Retrieved 17 April 2020.
  2. "Omidria EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 17 April 2020.
  3. Lawuyi LE, Gurbaxani A (2015). "The clinical utility of new combination phenylephrine/ketorolac injection in cataract surgery". Clinical Ophthalmology. Auckland, N.Z. 9: 1249–54. doi:10.2147/OPTH.S72321. PMC 4506037. PMID 26203214.
  4. "Drug Approval Package: Omidria (phenylephrine and ketorolac) Injection NDA #205388". U.S. Food and Drug Administration (FDA). 9 December 2014. Retrieved 17 April 2020.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.